Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年 12 月6日 8:20-8:50 B 棟8階 カンファレンス室.

Slides:



Advertisements
Similar presentations
The Diabetic Retinopathy Clinical Research Network
Advertisements

Journal Club General Medicine C- 4/3/14
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Serum Lipids and Proliferative Diabetic Retinopathy Klein BEK, Myers CE, Howard.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Pharmacologic Treatment of Pediatric Headaches El-Chammas K, Keyes J, Thompson N,
Journal Club 埼玉医科大学 総合医療センター 内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University 松田 昌文 Matsuda, Masafumi.
Atorvastatin in Factorial with Omega-3 fatty acid Risk Reduction in Diabetes …in an academic collaboration with.
MEDICATION SAFETY: Clozapine Initiation Chart Review
The Diabetic Retinopathy Clinical Research Network Repeated Intravitreous Ranibizumab Injections for DME and Risk of Sustained IOP Elevation or Need for.
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
Lipid Modifying Therapies and Risk of Pancreatitis: A Meta-analysis Presented by: MaCie Rogers Pharm.d Candidate 2013.
Henry N. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.
Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor- Positive Breast Cancer:
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年7月 24 日 8:20-8:50 B 棟8階 カンファレンス室.
Journal Club 埼玉医科大学 総合医療センター 内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University 松田 昌文 Matsuda, Masafumi.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年9月 25 日 8:20-8:50 B 棟8階 カンファレンス室.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
Effects of Pediatric Asthma Education on Hospitalizations and Emergency Department Visits: A Meta-Analysis June 3, 2007 Janet M. Coffman, PhD, Michael.
Interventions for nausea and vomiting in early pregnancy: a Cochrane Review Clinical
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年8月 21 日 8:20-8:50 B 棟8階 カンファレンス室.
Journal Club 埼玉医科大学 総合医療センター 内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University 松田 昌文 Matsuda, Masafumi.
The Diabetic Retinopathy Clinical Research Network
Journal Club 埼玉医科大学 総合医療センター 内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University 松田 昌文 Matsuda, Masafumi.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年7月3日 8:20-8:50 B 棟8階 カンファレンス室.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年8月 30 日 8:20-8:50 B 棟8階 カンファレンス室.
Placebo-Controls in Short-Term Clinical Trials of Hypertension Sana Al-Khatib, MD, MHS Assistant Professor of Medicine Division of Cardiology Duke University.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
How to Analyze Therapy in the Medical Literature (part 2)
Rimonabant in Obesity Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Jean-Pierre Despres RIO LIPIDS Trial.
Should developing countries continue to use older drugs for essential hypertension? A prescription survey in South Africa suggested that prescribers were.
© Copyright 2009 by the American Association for Clinical Chemistry Nonfasting Lipids, Lipoproteins, and Apolipoproteins in Individuals With and Without.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年6月 14 日 8:20-8:50 B 棟8階 カンファレンス室.
ABSTRACT Diabetes is a public health issue of growing magnitude. It currently ranks among the top ten leading causes of death in the United States. To.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2009 年 2 月 12 日 8:20-8:50 B 棟8階 カンファレンス室.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年7月 31 日 8:20-8:50 B 棟8階 カンファレンス室.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年5月 22 日 8:20-8:50 B 棟8階 カンファレンス室.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年 11 月 1 日 8:20-8:50 B 棟8階 カンファレンス室.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2009 年 2 月 5 日 8:20-8:50 B 棟8階 カンファレンス室.
A Diabetes Outcome Progression Trial
Thiazide diuretics, Potassium, and the Development of Diabetes A Quantitative Review Hypertension2006_219.
UKHDS (UKPDS): UK Hypertension in Diabetes Study Purpose To determine whether tight control of blood pressure (aiming for BP
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年1月 10 日 8:20-8:50 B 棟8階 カンファレンス室.
JAMA Ophthalmology Journal Club Slides: Complications of Vitrectomy for Diabetic Retinopathy Jackson TL, Johnston RL, Donachie PHJ, Williamson TH, Sparrow.
Is there evidence to justify different claims for different drug classes? Presentation to: Cardiovascular & Renal Drugs Advisory Committee Food & Drug.
Hilda Bastian NN/LM Pacific Southwest Region, webinar 10 April 2014 Systematic reviews and
C-1 Efficacy of the Combination: Meta-Analyses Donald A. Berry, Ph.D. Frank T. McGraw Memorial Chair of Cancer Research University of Texas M.D. Anderson.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年9月6日 8:20-8:50 B 棟8階 カンファレンス室.
Figure 1. Hazard ratios for progression-free survival analyzed with fixed effect model. Table 1: Relevant trials Table 2. Methodological quality Conclusions.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年5月1日 8:20-8:50 B 棟8階 カンファレンス室.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2006 年 12 月 14 日 8:20-8:50 B 棟8階 カンファレンス室.
Vitrase (Hyaluronidase for Injection) Advisory Committee Meeting March 17, 2003 Jennifer D. Harris, MD Medical Officer Division of Anti-inflammatory, Analgesic,
Selenium supplementation for the primary prevention of cardiovascular disease: a Cochrane review Clinical
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
Rene Descartes: “I think; therefore I am.”. 3.3: Data Ethics Statistics Chap 3: Designing Experiments.
Sources of systematic reviews Arash Etemadi, MD PhD Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences.
Journal Club Julie Shah, MD Milton S Hershey Medical Center Penn State University.
MIND-BODY THERAPIES FOR HYPERTENSION Systematic Review and Meta-Analysis Ather Ali, ND, MPH (1), David L. Katz, MD, MPH (1,2), Michael B. Bracken, PhD,
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
The Diabetic Retinopathy Clinical Research Network
R1. 이정미 / prof. 김우식. INTRODUCTION Reduction in low-density lipoprotein (LDL) cholesterol levels has proved to be highly effective in reducing rates of.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from participants in 26 randomised trials Lancet 2010;
ACCORD Eye Study Results
Volume 370, Issue 9600, Pages (November 2007)
Effects of Uric acid- lowering therapy on renal outcomes: a systematic review and meta-analysis Nephrol Dial Transplant (2014) 29: Vaughan Washco.
Assoc. Prof. Martin Valis, M.D., Ph.D.
Figure 5. Treatment of the checkpoint inhibitor related toxicity
Foroutan N1,2, Muratov S1,2, Levine M1,2
The Diabetic Retinopathy Clinical Research Network
Volume 373, Issue 9677, Pages (May 2009)
Presentation transcript:

Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年 12 月6日 8:20-8:50 B 棟8階 カンファレンス室

NHMRC Clinical Trials Centre (Prof A C Keech FRACP, Prof R J Simes FRACP, D Tse PhD, E Williamson PhD, A Merrifi eld PhD, R L O’Connell MMedStat), Royal Prince Alfred Hospital (Prof A C Keech, Prof R J Simes), Department of Ophthalmology (Prof P Mitchell FRANZCO), and Millennium Institute (M S Moffi tt DipTc), University of Sydney, NSW, Australia; Eye Hosptial, Helsinki University Central Hospital, Helsinki, Finland (P A Summanen FEBO); Department of Ophthalmology (J O’Day FRANZCO) and Royal Melbourne Hospital (Prof P G Colman FRACP), University of Melbourne, VIC, Australia; School of Medicine and Pharmacology, University of Western Australia Fremantle, WA, Australia (Prof T M E Davis MRCP); Department of Medicine (Prof M-R Taskinen MD) and Department of Ophthalmology (Prof L T Laatikainen FEBO), University of Helsinki, Helsinki, Finland; Royal Brisbane and Women’s Hospital, QLD, Australia (M C d’Emden FRACP); and Laboratoires Fournier SCA, Dijon, France (D C Crimet MD)

Laser treatment for diabetic retinopathy is often associated with visual field reduction and other ocular side-effects. Our aim was to assess whether long-term lipid-lowering therapy with fenofibrate could reduce the progression of retinopathy and the need for laser treatment in patients with type 2 diabetes mellitus. Background and Aim

The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study was a multinational randomised trial of 9795 patients aged 50–75 years with type 2 diabetes mellitus. Eligible patients were randomly assigned to receive fenofibrate 200 mg/day (n=4895) or matching placebo (n=4900). At each clinic visit, information concerning laser treatment for diabetic retinopathy—a prespecified tertiary endpoint of the main study—was gathered. Adjudication by ophthalmologists masked to treatment allocation defined instances of laser treatment for macularoedema, proliferative retinopathy, or other eye conditions. In a substudy of 1012 patients, standardised retinal photography was done and photographs graded with Early Treatment Diabetic Retinopathy Study (ETDRS) criteria to determine the cumulative incidence of diabetic retinopathy and its component lesions. Analyses were by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN Methods

Treatment with fenofibrate in individuals with type 2 diabetes mellitus reduces the need for laser treatment for diabetic retinopathy, although the mechanism of this eff ect does not seem to be related to plasma concentrations of lipids. Interpretation

The Parker Institute, Musculoskeletal Statistics Unit, Frederiksberg Hospital, Frederiksberg, Denmark (R Christensen MSc, P K Kristensen BSc, Prof H Bliddal MD); The Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen, Copenhagen, Denmark (P K Kristensen, Prof A Astrup MD); and Copenhagen University Library, Copenhagen, Denmark (E M Bartels DSc)

rimonabant

Since the prevalence of obesity continues to increase, there is a demand for effective and safe anti-obesity agents that can produce and maintain weight loss and improve comorbidity. We did a meta-analysis of all published randomised controlled trials to assess the efficacy and safety of the newly approved anti-obesity agent rimonabant. Background

We searched The Cochrane database and Controlled Trials Register, Medline via Pubmed, Embase via WebSpirs, Web of Science, Scopus, and reference lists up to July, We collected data from four double-blind, randomised controlled trials (including 4105 participants) that compared 20 mg per day rimonabant with placebo. Methods

Our findings suggest that 20 mg per day rimonabant increases the risk of psychiatric adverse events—ie, depressed mood disorders and anxiety—despite depressed mood being an exclusion criterion in these trials. Taken together with the recent US Food and Drug Administration finding of increased risk of suicide during treatment with rimonabant, we recommend increased alertness by physicians to these potentially severe psychiatric adverse reactions. Interpretation